Dulaglutide is a long-acting GLP-1 receptor agonist (once-weekly subcutaneous injection). Reduces HbA1c, weight, and cardiovascular risk.
Also known as: Trulicity
No documented drug–drug interactions for this medicine.
Dulaglutide is a weekly SC injection, independent of meals.
Inject on the same weekday, with or without a meal.
EMC-UK — Trulicity (dulaglutide) SmPC 4.2.
No documented disease interactions.
No documented pregnancy or breastfeeding information.
Clinical and educational support tool. The information does not replace a medical prescription or the opinion of a qualified healthcare professional.
Very long-acting (weekly) GLP-1 receptor agonist. Molecule chemically linked to IgG4 Fc.
Binds to the GLP-1 receptor, stimulating glucose-dependent insulin secretion and suppressing glucagon secretion. IgG4 Fc binding prolongs half-life.
Oral bioavailability: <1% (must be injected). SC absorption: ~65%. Tmax: 24-72 hours.
Metabolised by protease to amino acids and fatty acid. Does not interfere with CYP.
~4-5 days (allows weekly dosing). Elimination: ~60% urine (metabolites), ~30% faeces.
Medicines from the same therapeutic group (ATC classification) or the same pharmacological class.
